209 related articles for article (PubMed ID: 31924241)
1. A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer.
Goldstein LJ; Perez RP; Yardley D; Han LK; Reuben JM; Gao H; McCanna S; Butler B; Ruffini PA; Liu Y; Rosato RR; Chang JC
Breast Cancer Res; 2020 Jan; 22(1):4. PubMed ID: 31924241
[TBL] [Abstract][Full Text] [Related]
2. Phase Ib Pilot Study to Evaluate Reparixin in Combination with Weekly Paclitaxel in Patients with HER-2-Negative Metastatic Breast Cancer.
Schott AF; Goldstein LJ; Cristofanilli M; Ruffini PA; McCanna S; Reuben JM; Perez RP; Kato G; Wicha M
Clin Cancer Res; 2017 Sep; 23(18):5358-5365. PubMed ID: 28539464
[No Abstract] [Full Text] [Related]
3. Targeting CXCR1 on breast cancer stem cells: signaling pathways and clinical application modelling.
Brandolini L; Cristiano L; Fidoamore A; De Pizzol M; Di Giacomo E; Florio TM; Confalone G; Galante A; Cinque B; Benedetti E; Ruffini PA; Cifone MG; Giordano A; Alecci M; Allegretti M; Cimini A
Oncotarget; 2015 Dec; 6(41):43375-94. PubMed ID: 26517518
[TBL] [Abstract][Full Text] [Related]
4. Targeting CXCR1/2 significantly reduces breast cancer stem cell activity and increases the efficacy of inhibiting HER2 via HER2-dependent and -independent mechanisms.
Singh JK; Farnie G; Bundred NJ; Simões BM; Shergill A; Landberg G; Howell SJ; Clarke RB
Clin Cancer Res; 2013 Feb; 19(3):643-56. PubMed ID: 23149820
[TBL] [Abstract][Full Text] [Related]
5. A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida).
Goldstein LJ; Mansutti M; Levy C; Chang JC; Henry S; Fernandez-Perez I; Prausovà J; Staroslawska E; Viale G; Butler B; McCanna S; Ruffini PA; Wicha MS; Schott AF;
Breast Cancer Res Treat; 2021 Nov; 190(2):265-275. PubMed ID: 34476645
[TBL] [Abstract][Full Text] [Related]
6. An autocrine inflammatory forward-feedback loop after chemotherapy withdrawal facilitates the repopulation of drug-resistant breast cancer cells.
Jia D; Li L; Andrew S; Allan D; Li X; Lee J; Ji G; Yao Z; Gadde S; Figeys D; Wang L
Cell Death Dis; 2017 Jul; 8(7):e2932. PubMed ID: 28703802
[TBL] [Abstract][Full Text] [Related]
7. Blockade of CXCR1/2 chemokine receptors protects against brain damage in ischemic stroke in mice.
Sousa LF; Coelho FM; Rodrigues DH; Campos AC; Barcelos Lda S; Teixeira MM; Rachid MA; Teixeira AL
Clinics (Sao Paulo); 2013; 68(3):391-4. PubMed ID: 23644861
[TBL] [Abstract][Full Text] [Related]
8. Multiple anti-tumor effects of Reparixin on thyroid cancer.
Liotti F; De Pizzol M; Allegretti M; Prevete N; Melillo RM
Oncotarget; 2017 May; 8(22):35946-35961. PubMed ID: 28415590
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of CXCR1 and CXCR2 chemokine receptors attenuates acute inflammation, preserves gray matter and diminishes autonomic dysreflexia after spinal cord injury.
Marsh DR; Flemming JM
Spinal Cord; 2011 Mar; 49(3):337-44. PubMed ID: 20877331
[TBL] [Abstract][Full Text] [Related]
10. A pilot study on reparixin, a CXCR1/2 antagonist, to assess safety and efficacy in attenuating ischaemia-reperfusion injury and inflammation after on-pump coronary artery bypass graft surgery.
Opfermann P; Derhaschnig U; Felli A; Wenisch J; Santer D; Zuckermann A; Dworschak M; Jilma B; Steinlechner B
Clin Exp Immunol; 2015 Apr; 180(1):131-42. PubMed ID: 25402332
[TBL] [Abstract][Full Text] [Related]
11. Reparixin, an inhibitor of CXCR1 and CXCR2 receptor activation, attenuates blood pressure and hypertension-related mediators expression in spontaneously hypertensive rats.
Kim HY; Choi JH; Kang YJ; Park SY; Choi HC; Kim HS
Biol Pharm Bull; 2011; 34(1):120-7. PubMed ID: 21212529
[TBL] [Abstract][Full Text] [Related]
12. CXCL1-CXCR1/2 signaling is induced in human temporal lobe epilepsy and contributes to seizures in a murine model of acquired epilepsy.
Di Sapia R; Zimmer TS; Kebede V; Balosso S; Ravizza T; Sorrentino D; Castillo MAM; Porcu L; Cattani F; Ruocco A; Aronica E; Allegretti M; Brandolini L; Vezzani A
Neurobiol Dis; 2021 Oct; 158():105468. PubMed ID: 34358616
[TBL] [Abstract][Full Text] [Related]
13. CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts.
Ginestier C; Liu S; Diebel ME; Korkaya H; Luo M; Brown M; Wicinski J; Cabaud O; Charafe-Jauffret E; Birnbaum D; Guan JL; Dontu G; Wicha MS
J Clin Invest; 2010 Feb; 120(2):485-97. PubMed ID: 20051626
[TBL] [Abstract][Full Text] [Related]
14. Recent advances reveal IL-8 signaling as a potential key to targeting breast cancer stem cells.
Singh JK; Simões BM; Howell SJ; Farnie G; Clarke RB
Breast Cancer Res; 2013; 15(4):210. PubMed ID: 24041156
[TBL] [Abstract][Full Text] [Related]
15. Targeting CXCR1/2 Does Not Improve Insulin Secretion After Pancreatic Islet Transplantation: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial in Type 1 Diabetes.
Maffi P; Lundgren T; Tufveson G; Rafael E; Shaw JAM; Liew A; Saudek F; Witkowski P; Golab K; Bertuzzi F; Gustafsson B; Daffonchio L; Ruffini PA; Piemonti L;
Diabetes Care; 2020 Apr; 43(4):710-718. PubMed ID: 32019854
[TBL] [Abstract][Full Text] [Related]
16. IL-8 and CXCR1 expression is associated with cancer stem cell-like properties of clear cell renal cancer.
Corrò C; Healy ME; Engler S; Bodenmiller B; Li Z; Schraml P; Weber A; Frew IJ; Rechsteiner M; Moch H
J Pathol; 2019 Jul; 248(3):377-389. PubMed ID: 30883740
[TBL] [Abstract][Full Text] [Related]
17. Development of a systemically-active dual CXCR1/CXCR2 allosteric inhibitor and its efficacy in a model of transient cerebral ischemia in the rat.
Garau A; Bertini R; Mosca M; Bizzarri C; Anacardio R; Triulzi S; Allegretti M; Ghezzi P; Villa P
Eur Cytokine Netw; 2006 Mar; 17(1):35-41. PubMed ID: 16613761
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of interleukin 8/C‑X-C chemokine receptor 1,/2 signaling reduces malignant features in human pancreatic cancer cells.
Fu S; Chen X; Lin HJ; Lin J
Int J Oncol; 2018 Jul; 53(1):349-357. PubMed ID: 29749433
[TBL] [Abstract][Full Text] [Related]
19. Targeting CXCR1/2 in the first multicenter, double-blinded, randomized trial in autologous islet transplant recipients.
Witkowski P; Wijkstrom M; Bachul PJ; Morgan KA; Levy M; Onaca N; Chaidarun SS; Gardner T; Shapiro AMJ; Posselt A; Ahmad SA; Daffonchio L; Ruffini PA; Bellin MD
Am J Transplant; 2021 Nov; 21(11):3714-3724. PubMed ID: 34033222
[TBL] [Abstract][Full Text] [Related]
20. CXCR1/2 inhibition enhances pancreatic islet survival after transplantation.
Citro A; Cantarelli E; Maffi P; Nano R; Melzi R; Mercalli A; Dugnani E; Sordi V; Magistretti P; Daffonchio L; Ruffini PA; Allegretti M; Secchi A; Bonifacio E; Piemonti L
J Clin Invest; 2012 Oct; 122(10):3647-51. PubMed ID: 22996693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
